Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REDEFINE 9

REDEFINE 9

CagriSema · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CagriSema
Population
obesity
Phase
3
Duration
68 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
CagriSema 1.0/1.0 mgobesity68—−21.0 % vs −2.0 %
Δ −19.0 pp
————————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (1)
  • CagriSema 1.0/1.0 mg · weight_eff · company announcement
    CagriSema 1.0 mg/1.0 mg provided a weight reduction of 21.0% versus 2.0%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REDEFINE 9. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-9/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.